Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316)

Dong Min Shin; Jongeun Lee; Hyungrye Noh; Donghwi Jang; Se Jin Oh; Ji Hye Park; Jong Hee Lee

doi:10.5021/ad.35.003

Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316)

Dong Min Shin
, Jongeun Lee
, Hyungrye Noh
, Donghwi Jang
, Se Jin Oh
, Ji Hye Park
, Jong Hee Lee

Department of Dermatology

Sungkyunkwan University

Research output: Contribution to journal › Comment/debate

Abstract

The botulinum toxin type A 150 kD neurotoxin (Coretox; Medytox, Seoul, Korea) was used in this clinical study. It has not been approved as “incobotulinum toxin A” by FDA yet and therefore, the term “incobotulinum toxin A (previously abbreviated as BTXAi in the manuscript)” is changed into “botulinum toxin A 150 kD neurotoxin (abbreviated as BTXA150).”

Original language	English
Pages (from-to)	88
Number of pages	1
Journal	Annals of Dermatology
Volume	35
Issue number	1
DOIs	https://doi.org/10.5021/ad.35.003
State	Published - Feb 2023

Access to Document

10.5021/ad.35.003

Fingerprint

Dive into the research topics of 'Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316)'. Together they form a unique fingerprint.

Cite this

Shin, D. M., Lee, J., Noh, H., Jang, D., Oh, S. J., Park, J. H., & Lee, J. H. (2023). Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316). Annals of Dermatology, 35(1), 88. https://doi.org/10.5021/ad.35.003

@article{bd632479bbb0469883451234f2708e17,

title = "Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316)",

abstract = "The botulinum toxin type A 150 kD neurotoxin (Coretox; Medytox, Seoul, Korea) was used in this clinical study. It has not been approved as “incobotulinum toxin A” by FDA yet and therefore, the term “incobotulinum toxin A (previously abbreviated as BTXAi in the manuscript)” is changed into “botulinum toxin A 150 kD neurotoxin (abbreviated as BTXA150).”",

author = "Shin, \{Dong Min\} and Jongeun Lee and Hyungrye Noh and Donghwi Jang and Oh, \{Se Jin\} and Park, \{Ji Hye\} and Lee, \{Jong Hee\}",

year = "2023",

month = feb,

doi = "10.5021/ad.35.003",

language = "English",

volume = "35",

pages = "88",

journal = "Annals of Dermatology",

issn = "1013-9087",

publisher = "Korean Dermatological Association",

number = "1",

}

Shin, DM, Lee, J, Noh, H, Jang, D, Oh, SJ, Park, JH & Lee, JH 2023, 'Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316)', Annals of Dermatology, vol. 35, no. 1, pp. 88. https://doi.org/10.5021/ad.35.003

Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316). / Shin, Dong Min; Lee, Jongeun; Noh, Hyungrye et al.
In: Annals of Dermatology, Vol. 35, No. 1, 02.2023, p. 88.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316)

AU - Shin, Dong Min

AU - Lee, Jongeun

AU - Noh, Hyungrye

AU - Jang, Donghwi

AU - Oh, Se Jin

AU - Park, Ji Hye

AU - Lee, Jong Hee

PY - 2023/2

Y1 - 2023/2

N2 - The botulinum toxin type A 150 kD neurotoxin (Coretox; Medytox, Seoul, Korea) was used in this clinical study. It has not been approved as “incobotulinum toxin A” by FDA yet and therefore, the term “incobotulinum toxin A (previously abbreviated as BTXAi in the manuscript)” is changed into “botulinum toxin A 150 kD neurotoxin (abbreviated as BTXA150).”

AB - The botulinum toxin type A 150 kD neurotoxin (Coretox; Medytox, Seoul, Korea) was used in this clinical study. It has not been approved as “incobotulinum toxin A” by FDA yet and therefore, the term “incobotulinum toxin A (previously abbreviated as BTXAi in the manuscript)” is changed into “botulinum toxin A 150 kD neurotoxin (abbreviated as BTXA150).”

UR - https://www.scopus.com/pages/publications/85149841168

U2 - 10.5021/ad.35.003

DO - 10.5021/ad.35.003

M3 - Comment/debate

AN - SCOPUS:85149841168

SN - 1013-9087

VL - 35

SP - 88

JO - Annals of Dermatology

JF - Annals of Dermatology

IS - 1

ER -

Erratum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek (Annals of Dermatology (2022) 34:6 (442-450) DOI: 10.5021/ad.21.316)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this